EVALUATION OF AS PATIENTS

Preview:

DESCRIPTION

EVALUATION OF AS PATIENTS. YEAR 2005. GENERAL DEMOGRAPHICS GENDER. PATIENTS’ AGE GROUPS. DURATION OF DISEASE AGE. DIFFERENCE OF MS AT POSTTREATMENT. DIFFERENCE OF VAS ( PAIN ) AT POSTTREATMENT. DIFFERENCE OF OWB AT POSTTREATMENT. DIFFERENCE OF MHAQ AT POSTTREATMENT. - PowerPoint PPT Presentation

Citation preview

EVALUATION OF AS PATIENTSEVALUATION OF AS PATIENTS

YEAR 2005YEAR 2005

GENERAL DEMOGRAPHICSGENERAL DEMOGRAPHICSGENDERGENDER

♀ ♀ %% ♂♂ %% Total Total

ASAS 147147 35,335,3 269269 64,764,7 416416

PATIENTS’ AGE GROUPSPATIENTS’ AGE GROUPS

-20-20 %%21-21-4040 %%

41-41-6060 %% 61+61+ %% Mean Mean

ASAS 00 00 8080 19,219,2 281281 67,567,5 5555 13,313,3 49,749,7

DURATION OF DISEASE AGEDURATION OF DISEASE AGE

-10-10 %%11-11-2020 %%

21-21-3030 %% 31+31+ %% MeanMean

ASAS 122122 29,329,3 156156 37,537,5 101101 24,324,33737

8,98,9 16,916,9

DIFFERENCE OF MS DIFFERENCE OF MS AT POSTTREATMENTAT POSTTREATMENT

MS1MS1

--

MS2MS2

Dec Dec %% IncInc %% SameSame %%

ASAS 359359 86,386,3 1717 4,14,1 4040 9,69,6

MEANMEAN MS1MS1 MS2MS2

ASAS 5959 21,721,7

DIFFERENCE OF VAS ( PAIN ) DIFFERENCE OF VAS ( PAIN ) AT POSTTREATMENTAT POSTTREATMENT

VAS1VAS1

--

VAS2VAS2

(pain)(pain)

Dec Dec %% IncInc %% SameSame %%

ASAS 378378 90,990,9 3434 8,18,1 44 11

MEANMEAN VAS1VAS1 VAS2VAS2

ASAS 47,447,4 18,318,3

DIFFERENCE OF OWB DIFFERENCE OF OWB AT POSTTREATMENTAT POSTTREATMENT

OWB1OWB1

--

OWB2OWB2

Dec Dec %% IncInc %% SameSame %%

ASAS 387387 92,892,8 2424 5,75,7 66 1,51,5

MEANMEAN OWB1OWB1 OWB2OWB2

ASAS 51,851,8 19,919,9

DIFFERENCE OF MHAQ DIFFERENCE OF MHAQ AT POSTTREATMENTAT POSTTREATMENT

MHAQ1MHAQ1

--

MHAQ2MHAQ2

Dec Dec %% IncInc %% SameSame %%

ASAS 338338 81,281,2 1919 4,54,5 5959 14,314,3

MEANMEAN MHAQ1MHAQ1 MHAQ2MHAQ2

ASAS 15,1815,18 11,6411,64

DIFFERENCE OF BASFI DIFFERENCE OF BASFI AT POSTTREATMENTAT POSTTREATMENT

BASFI1BASFI1

--

BASFI2BASFI2Dec Dec %% IncInc %% SameSame %%

ASAS 394394 94,794,7 1818 4,34,3 44 11

MEANMEAN BASFI1BASFI1 BASFI2BASFI2

ASAS 39,2439,24 17,5117,51

DIFFERENCE OF BASDAI DIFFERENCE OF BASDAI AT POSTTREATMENTAT POSTTREATMENT

BASDAI1BASDAI1

--

BASDAI2BASDAI2Dec Dec %% IncInc %% SameSame %%

ASAS 391391 9494 2424 5,75,7 11 0,30,3

MEANMEAN BASDAI1BASDAI1 BASDAI2BASDAI2

ASAS 44,244,2 17,6517,65

DIFFERENCE OF SCHOBERDIFFERENCE OF SCHOBERAT POSTTREATMENTAT POSTTREATMENT

SCHB1SCHB1

--

SCHB2SCHB2Dec Dec %% IncInc %% SameSame %%

ASAS 2121 5,15,1 267267 64,264,2 128128 30,730,7

MEANMEAN SCHB1SCHB1 SCHB2SCHB2

ASAS 31,2531,25 36,6736,67

DIFFERENCE OF Thorax Expansion DIFFERENCE OF Thorax Expansion AT POSTTREATMENTAT POSTTREATMENT

ThExp1ThExp1

--

ThExp2ThExp2Dec Dec %% IncInc %% SameSame %%

ASAS 1313 3,13,1 366366 8888 3737 8,98,9

MEANMEAN ThExp1ThExp1 ThExp2ThExp2

ASAS 34,334,3 48,6648,66

DIFFERENCE OF Wall-Occiput DistanceDIFFERENCE OF Wall-Occiput DistanceAT POSTTREATMENTAT POSTTREATMENT

WO1WO1

--

WO2WO2Dec Dec %% IncInc %% SameSame %%

ASAS 247247 59,459,4 55 1,21,2 165165 39,439,4

MEANMEAN WO1WO1 WO2WO2

ASAS 55,955,9 37,4837,48

ANALGESIC USAGE ANALGESIC USAGE AT PRETREATMENTAT PRETREATMENT

AA A-A- %% A+A+ %%

ASAS 266266 63,9463,94 150150 36,0536,05

DIFFERENCE OF “A” USAGE AT DIFFERENCE OF “A” USAGE AT POSTTREATMENTPOSTTREATMENT

AA SameSame %% Dec Dec %% IncInc %% Sep Sep %%

ASAS 6969 4646 5353 35,335,3 66 44 2222 14,714,7

NSAID USAGE NSAID USAGE AT PRETREATMENTAT PRETREATMENT

NSAIDNSAID NSAID-NSAID- %% NSAID+NSAID+ %%

ASAS 126126 30,330,3 290290 69,769,7

DIFFERENCE OF NSAID USAGE DIFFERENCE OF NSAID USAGE AT POST-TREATMENTAT POST-TREATMENT

NSAIDNSAID SameSame %%Dec Dec

%% IncInc %% Sep Sep %%

ASAS 169169 58,358,3 7777 26,526,5 22 0,70,7 4242 14,514,5

STEROID USAGE STEROID USAGE AT PRE-TREATMENTAT PRE-TREATMENT

STRSTR STR-STR- %% STR+STR+ %%

ASAS 392392 94,294,2 2424 5,85,8

DIFFERENCE OF “STR” USAGE DIFFERENCE OF “STR” USAGE AT POSTTREATMENTAT POSTTREATMENT

STRSTR SameSame %% Dec Dec %% IncInc %% Sep Sep %%

ASAS 1717 70,870,8 33 12,512,5 11 4,24,2 33 12,512,5

USAGE OF OTHER DRUGS USAGE OF OTHER DRUGS AT PRETREATMENTAT PRETREATMENT

OTHOTH OTHER-OTHER- %% OTHER+OTHER+ %%

ASAS 313313 75,375,3 103103 24,724,7

DIFFERENCE OF OTHER DRUGS DIFFERENCE OF OTHER DRUGS AT POSTTREATMENTAT POSTTREATMENT

OTHOTH SameSame %% Dec Dec %% IncInc %% Sep Sep %%

ASAS 9999 96,296,2 44 3,83,8 00 00 00 00

MOSTLY SEEN MOSTLY SEEN SECONDARY DISEASESSECONDARY DISEASES

SEC.SEC.

DIS.DIS.

NONO

%%

YESYES

%%

HTHT

%%

CADCAD

%%

DMDM

%%COLDCOLD

%%

CACA

%%DEPRDEPR

%%

TROITROI

%%

OTHOTH

%%

ASAS172172

41,3441,34

244244

58,6558,65

7171

29,0929,09

2121

8,68,6

1414

5,735,73

2525

10,2410,24

88

3,273,27

88

3,273,27

2222

9,019,01

140140

57,3757,37

DAILY POLICLINIC CASESDAILY POLICLINIC CASES

POLIPOLICLNCLN

NONO

%%

YESYES

%%

TRATRA

%%

EYEEYE

%%

URSURS

%%

DERDER

%%

DIARDIAR

%%

PAINPAIN

%%

USEUSE

%%

OTHOTH

%%

ASAS284284

68,2668,26

132132

31,7331,73

66

4,544,54

99

6,816,81

2222

16,6616,66

99

6,816,81

1313

9,849,84

6060

45,4545,45

11

0,750,75

2929

21,9621,96

PATIENTS WHO WERE PATIENTS WHO WERE REFERRED TO HOSPITALREFERRED TO HOSPITAL

CONCONSULTSULT

NONO

%%

MRMR

%%

EYEEYE

%%

ENTENT

%%DERDER

%%

ORTORT

%%

NEUNEU

%%

ASAS405405

97,3597,35

11

0,240,24

33

0,720,72

11

0,240,24

11

0,240,24

22

0,480,48

33

0,720,72

THANK YOU THANK YOU

FOR YOUR ATTENTIONFOR YOUR ATTENTION

Recommended